TAS-120-202, Futibatinib in Patients with Specific FGFR Aberrations

• Research type

  Research Study

• Full title

  A PHASE 2 STUDY OF FUTIBATINIB IN PATIENTS WITH SPECIFIC FGFR ABERRATIONS

• IRAS ID

  1003232

• Contact name

  Hendrik-Tobias Arkenau

• Contact email

  Tobias.Arkenau@hcahealthcare.co.uk

• Sponsor organisation

  Taiho Oncology Inc.

• Eudract number

  2019-004084-49

• Clinicaltrials.gov Identifier

  NCT04189445

• REC name

  North West - Haydock Research Ethics Committee

• REC reference

  20/NW/0247

• Date of REC Opinion

  23 Jun 2020

• REC opinion

  Further Information Favourable Opinion